Promoted Content

Promoted Content

All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Addex Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Nano medicine and Drug Delivery

Participation Not Confirmed

Update your events

Addex and the SIB Swiss Institute of Bioinformatics Receive Innosuisse Grant to Repurpose Potent Dopamine Antagonist

Contact the Supplier

Lead Product(s): ADX10061

Therapeutic Area: Neurology Product Name: ADX10061

Highest Development Status: Discovery Product Type: Small molecule

Partner/Sponsor/Collaborator: Innosuisse

Deal Size: $0.6 million Upfront Cash: Undisclosed

Deal Type: Funding August 27, 2020

Details:

CHF600K Innosuisse grant will support SIB's computational approaches to identify new therapeutic indications for ADX10061, a potent and selective dopamine D1 receptor antagonist.